Antwort

Dtsch Med Wochenschr 2017; 142(20): 1560
DOI: 10.1055/s-0043-115001

Leserbrief

Authors

Volker Schulze

¹Klinik für Kardiologie, Pneumologie und Angiologie, Herzzentrum der Heinrich-Heine-Universität, Düsseldorf
Tobias Zeus

¹Klinik für Kardiologie, Pneumologie und Angiologie, Herzzentrum der Heinrich-Heine-Universität, Düsseldorf
Horst Sievert

²Cardio Vasculäres Centrum CVC, Frankfurt

Literatur
1 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: [...]. Eur Heart J 2016;
2 Holmes DR, Reddy VY, Buchbinder M. et al. The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial. Am Heart J 2017; 189: 68-74
3 Boersma LV, Schmidt B, Betts TR. et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: [...]. Eur Heart J 2016; 37: 2465-2474
4 Reddy VY, Doshi SK, Sievert H. et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: [...]. Circulation 2013; 127: 720-729
5 Bergmann MW, Betts TR, Sievert H. et al. Early Anticoagulation drug regimens after WATCHMAN Left Atrial Appendage Closure: [...]. EuroIntervention 2017;
6 Bordignon S, Perrotta L, Dugo D. et al. Electrical isolation of the left atrial appendage by MAZE-like catheter substrate modification: [...]. J Cardiovasc Electrophysiol 2017;
7 Piccini JP, Sievert H, Patel MR. Left atrialappendage occlusion: rationale, evidence, devices, and patient selection. Eu Heart J 2017; 38: 869-876